Theravance Biopharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Madison Avenue International LP, along with affiliated entities, has reported a beneficial ownership of 9,212,252 ordinary shares, representing 17.7% of Theravance Biopharma, Inc.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 6.5% Passive Stake in Theravance Biopharma
BlackRock, Inc. has filed an updated Schedule 13G, revealing a 6.5% beneficial ownership stake in Theravance Biopharma, Inc. as of March 31, 2025.
NASDAQ
Newtyn Management, LLC and its affiliates have disclosed a combined 9.7% beneficial ownership stake in Theravance Biopharma, Inc., as of December 31, 2024.